Cargando…

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas

BACKGROUND: Isocitrate dehydrogenase (IDH) mutations are thought to represent an early oncogenic event in glioma evolution, found with high penetrance across tumor cells; however, in rare cases, IDH mutation may exist only in a small subset of the total tumor cells (subclonal IDH mutation). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vij, Meenakshi, Yokoda, Raquel T, Rashidipour, Omid, Tran, Ivy, Vasudevaraja, Varshini, Snuderl, Matija, Yong, Raymund L, Cobb, William S, Umphlett, Melissa, Walker, Jamie M, Tsankova, Nadejda M, Richardson, Timothy E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263115/ https://www.ncbi.nlm.nih.gov/pubmed/37324217 http://dx.doi.org/10.1093/noajnl/vdad069

Ejemplares similares

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping
por: Lyon, James F., et al.
Publicado: (2021)

Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas
por: Mirchia, Kanish, et al.
Publicado: (2019)

Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
por: Liu, Elisa K, et al.
Publicado: (2022)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report
por: Umphlett, Melissa, et al.
Publicado: (2020)

Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
por: Bledea, Ramona, et al.
Publicado: (2019)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant
por: Yano, Hirohito, et al.
Publicado: (2021)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors
por: Vougiouklakis, Theodore, et al.
Publicado: (2020)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

Chromosomal instability in adult-type diffuse gliomas
por: Richardson, Timothy E., et al.
Publicado: (2022)

Total copy number variation as a prognostic factor in adult astrocytoma subtypes
por: Mirchia, Kanish, et al.
Publicado: (2019)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas
por: Feraco, Paola, et al.
Publicado: (2020)

Naturopathic Treatment of Grade III Oligodendroglioma With Progression to Grade IV Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma and the Development of Spinal Gliomatosis
por: Terrani, Kristina F, et al.
Publicado: (2023)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis
por: Suwala, Abigail K., et al.
Publicado: (2020)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
por: Marker, Daniel F., et al.
Publicado: (2020)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis
por: Geramizadeh, Bita, et al.
Publicado: (2021)

Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA
por: Makino, Yasuhide, et al.
Publicado: (2021)

Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas
por: Lasocki, Arian, et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant
por: Sohn, Beomseok, et al.
Publicado: (2021)

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis
por: Stewart, James, et al.
Publicado: (2022)

Novel insight into histological and molecular astrocytoma, IDH‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors
por: Chen, Wenlin, et al.
Publicado: (2023)

Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma
por: Minniti, Giuseppe, et al.
Publicado: (2023)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment
por: Kurdi, Maher, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ck4dae8vouc114qv1q751rn7gq